'We remember India's generosity': US to 'divert' vaccine resources to Serum Institute

Published on Apr 27, 2021 01:23 PM IST

"What we are doing is diverting our own order of our own supplies to the Serum Institute for their manufacturing," a senior administration official said, elaborating on the exact nature of the assistance that the US is providing to India in view of the recent Covid-19 surge.

President Joe Biden speaks about Covid-19 vaccinations at the White House, in Washington. (File Photo / AP)
President Joe Biden speaks about Covid-19 vaccinations at the White House, in Washington. (File Photo / AP)
By | Written by Joydeep Bose | Edited by Avik Roy

The United States on Tuesday said that it remembers "India's generosity" in the early days of the pandemic and will hence be delivering raw materials to the Serum Institute of India (SII) for the production of the Oxford-AstraZeneca Covishield vaccine, with an aim to help India tide over the current wave of the coronavirus disease.

In a White House press briefing earlier this day, senior officials of the Biden-Harris administration said that the United States was "diverting" its own order of raw materials to the Serum Institute in light of the current crisis as this was the "most effective and rapid step" that could be taken at this stage to provide support.

Also Read: How Biden admin changed stance on supply of vaccine raw materials to India

"As requested by the Government of India, we will be providing raw materials for the production of the AstraZeneca Covishield vaccine at the Serum Institute of India," a senior administration official said, elaborating on the "complexities of the global supply chain" and the exact nature of the assistance that the US is providing to India.

"Given that there is not enough of the supply for the entire global manufacturing effort and in light of the current crisis, we, the United States, are diverting our order to India. So, I want to be clear here that we did not intervene with the manufacturer to make them fill the Serum Institute’s order; we don’t have that power. Instead, what we are doing is diverting our own order of our own supplies to the Serum Institute for their manufacturing," the official said.

Providing further details, the senior administration official said that the Defense Production Act (DPA) in the US requires American companies to prioritise US government contracts over others. "But what it does not mean is an export ban or a de facto ban or an embargo or any restrictions on sales to any other outside clients or customers anywhere. Companies are able to export however they need," he said.

Also Read: Joe Biden’s wartime law use blocks India’s vaccine ramp-up

Adding that the DPA doesn't cause any shortages in global supplies, the official pointed out that the US government doesn't even have the power to intervene with the manufacturing companies' orders. Hence, it was diverting its own supplies to India in view of the recent surge in Covid-19.

The official further said that the United States Agency for International Development (USAID) and the Centers for Disease Control and Prevention (CDC) will be providing additional technical assistance and materials to strengthen vaccine communications between India and the US and support "vaccine readiness at the national and sub-national levels."

US experts, however, believe that the Biden administration can do more. The US Chamber of Commerce had earlier last week called on the White House to release millions of AstraZeneca vaccine doses from its stockpile, which the US is unlikely to use because Pfizer-BioNTech, Moderna and Johnson & Johnson shots will more than meet its needs. The US has also not authorised the AstraZeneca shot.

Get Latest India Newsalong with Latest Newsand Top Headlinesfrom India and around the world.
SHARE THIS ARTICLE ON
SHARE
Story Saved
OPEN APP
×
Saved Articles
Following
My Reads
My Offers
Sign out
New Delhi 0C
Monday, February 06, 2023
Start 15 Days Free Trial Subscribe Now
Register Free and get Exciting Deals